KZIA Kazia Therapeutics ADRs

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, engaged in developing anti-cancer drugs. It has two clinical staged drug development candidates and an early stage discovery program. This is an ADR of a company whose stock trades outside of the U.S. as the symbol AT:KZA.

$10.66  -0.11 (-1.02%)
As of 10/22/2021 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Australia
Country of incorporation:  Australia
IPO date:  02/11/2013
Outstanding shares:  132,012,209
Average volume:  26,801
Market cap:   $1,421,771,491
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    48669G105
ISIN:        US48669G1058
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.71
PS ratio:   0.00
Return on equity:   -43.05%
Net income %:   -32,065.43%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy